Living Cell Technologies Limited (LVCLF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 3.19 Million AUD | -24.2% |
| 2023 | 4.21 Million AUD | -1.45% |
| 2022 | 4.27 Million AUD | 160.27% |
| 2021 | 1.64 Million AUD | -51.57% |
| 2020 | 3.39 Million AUD | -41.12% |
| 2019 | 5.75 Million AUD | -24.3% |
| 2018 | 7.6 Million AUD | -12.49% |
| 2017 | 8.69 Million AUD | 37.73% |
| 2016 | 6.31 Million AUD | 15.52% |
| 2015 | 5.46 Million AUD | -43.46% |
| 2014 | 9.66 Million AUD | -32.03% |
| 2013 | 14.21 Million AUD | -8.41% |
| 2012 | 15.52 Million AUD | 107.76% |
| 2011 | 7.47 Million AUD | 7.61% |
| 2010 | 6.94 Million AUD | 6.82% |
| 2009 | 6.5 Million AUD | -46.9% |
| 2008 | 12.24 Million AUD | 220.67% |
| 2007 | 3.81 Million AUD | -10.35% |
| 2006 | 4.25 Million AUD | 7.95% |
| 2005 | 3.94 Million AUD | 201.25% |
| 2004 | 1.3 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 3.19 Million AUD | -24.2% |
| 2024 Q1 | 3.75 Million AUD | -12.04% |
| 2024 Q3 | 3.19 Million AUD | -15.08% |
| 2024 Q4 | 3.19 Million AUD | 0.0% |
| 2024 Q2 | 3.75 Million AUD | 0.0% |
| 2023 FY | 4.21 Million AUD | -1.45% |
| 2023 Q4 | 4.27 Million AUD | 1.47% |
| 2023 Q1 | 3.11 Million AUD | -27.1% |
| 2023 Q2 | 3.11 Million AUD | 0.0% |
| 2023 Q3 | 4.21 Million AUD | 35.18% |
| 2022 FY | 4.27 Million AUD | 160.27% |
| 2022 Q4 | 4.27 Million AUD | 0.0% |
| 2022 Q3 | 4.27 Million AUD | -4.08% |
| 2022 Q2 | 4.45 Million AUD | 0.0% |
| 2022 Q1 | 4.45 Million AUD | 171.33% |
| 2021 Q3 | 1.64 Million AUD | -39.63% |
| 2021 Q4 | 1.64 Million AUD | 0.0% |
| 2021 Q1 | 2.72 Million AUD | -19.78% |
| 2021 Q2 | 2.72 Million AUD | 0.0% |
| 2021 FY | 1.64 Million AUD | -51.57% |
| 2020 Q2 | 4.62 Million AUD | 0.0% |
| 2020 FY | 3.39 Million AUD | -41.12% |
| 2020 Q3 | 3.39 Million AUD | -26.67% |
| 2020 Q1 | 4.62 Million AUD | -19.71% |
| 2020 Q4 | 3.39 Million AUD | 0.0% |
| 2019 Q1 | 6.13 Million AUD | -19.41% |
| 2019 FY | 5.75 Million AUD | -24.3% |
| 2019 Q2 | 6.13 Million AUD | 0.0% |
| 2019 Q3 | 5.75 Million AUD | -6.07% |
| 2019 Q4 | 5.75 Million AUD | 0.0% |
| 2018 Q4 | 7.6 Million AUD | 0.0% |
| 2018 Q3 | 7.6 Million AUD | 24.48% |
| 2018 Q2 | 6.11 Million AUD | 0.0% |
| 2018 Q1 | 6.11 Million AUD | -29.7% |
| 2018 FY | 7.6 Million AUD | -12.49% |
| 2017 FY | 8.69 Million AUD | 37.73% |
| 2017 Q2 | 9.85 Million AUD | 0.0% |
| 2017 Q3 | 8.69 Million AUD | -11.78% |
| 2017 Q4 | 8.69 Million AUD | 0.0% |
| 2017 Q1 | 9.85 Million AUD | 56.13% |
| 2016 Q1 | 4.57 Million AUD | -16.26% |
| 2016 Q3 | 6.31 Million AUD | 37.95% |
| 2016 FY | 6.31 Million AUD | 15.52% |
| 2016 Q4 | 6.31 Million AUD | 0.0% |
| 2016 Q2 | 4.57 Million AUD | 0.0% |
| 2015 Q2 | 10.94 Million AUD | 0.0% |
| 2015 FY | 5.46 Million AUD | -43.46% |
| 2015 Q4 | 5.46 Million AUD | 0.0% |
| 2015 Q3 | 5.46 Million AUD | -50.08% |
| 2015 Q1 | 10.94 Million AUD | 13.27% |
| 2014 Q1 | 13.61 Million AUD | -4.25% |
| 2014 FY | 9.66 Million AUD | -32.03% |
| 2014 Q4 | 9.66 Million AUD | 0.0% |
| 2014 Q3 | 9.66 Million AUD | -29.01% |
| 2014 Q2 | 13.61 Million AUD | 0.0% |
| 2013 FY | 14.21 Million AUD | -8.41% |
| 2013 Q4 | 14.21 Million AUD | -0.01% |
| 2013 Q3 | 14.21 Million AUD | 0.0% |
| 2012 FY | 15.52 Million AUD | 107.76% |
| 2012 Q4 | 15.52 Million AUD | 0.0% |
| 2011 FY | 7.47 Million AUD | 7.61% |
| 2011 Q4 | 7.47 Million AUD | 0.0% |
| 2010 FY | 6.94 Million AUD | 6.82% |
| 2010 Q4 | 6.94 Million AUD | 0.0% |
| 2009 Q4 | 6.5 Million AUD | 0.0% |
| 2009 FY | 6.5 Million AUD | -46.9% |
| 2008 Q4 | 12.24 Million AUD | 0.0% |
| 2008 FY | 12.24 Million AUD | 220.67% |
| 2007 Q4 | 3.81 Million AUD | 0.0% |
| 2007 FY | 3.81 Million AUD | -10.35% |
| 2006 Q4 | 4.25 Million AUD | 0.0% |
| 2006 FY | 4.25 Million AUD | 7.95% |
| 2005 FY | 3.94 Million AUD | 201.25% |
| 2005 Q4 | 3.94 Million AUD | 0.0% |
| 2004 FY | 1.3 Million AUD | 0.0% |
| 2004 Q4 | 1.3 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 93.942% |
| Skye Bioscience, Inc. | 11.94 Million USD | 73.261% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 97.548% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -478.262% |
| Qrons Inc. | 420.00 USD | -760066.19% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 78.073% |
| CSL Limited | 38.02 Billion USD | 99.992% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 69.749% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -63.043% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -802.869% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 88.575% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -564.374% |
| Rebus Holdings, Inc. | 5000.00 USD | -63753.96% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -138112.035% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -314.29% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -364.402% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 91.781% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 55.778% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4081.442% |
| SQZ Biotechnologies Company | 107.18 Million USD | 97.021% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -122.949% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -4311.937% |
| Mesoblast Limited | 667.9 Million USD | 99.522% |
| Marizyme, Inc. | 22.01 Million USD | 85.498% |
| Genus plc | 1.02 Billion USD | 99.69% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -135.042% |
| Pharming Group N.V. | 462.85 Million USD | 99.31% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 3.632% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -539.769% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -409.202% |
| ContraFect Corporation | 20.67 Million USD | 84.561% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -717.873% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -735.398% |
| IMV Inc. | 31.33 Million USD | 89.811% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 22.994% |
| MultiCell Technologies, Inc. | 126.22 USD | -2529370.765% |
| ONE Bio Corp. | 70.08 Million USD | 95.445% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -239.761% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 97.516% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -639.54% |
| Q BioMed Inc. | 3.51 Million USD | 9.183% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 90.924% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1121.959% |
| Biomind Labs Inc. | 73.81 Thousand USD | -4225.036% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.285% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -120.362% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 89.363% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -16.253% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -22.645% |
| GB Sciences, Inc. | 103.44 Thousand USD | -2986.462% |
| Alpha Cognition Inc. | 2.45 Million USD | -30.199% |
| HST Global, Inc. | 1526.00 USD | -209120.052% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -223.158% |
| Halberd Corporation | 10.13 Thousand USD | -31414.145% |
| Enzolytics Inc. | 361.7 Million USD | 99.117% |
| Agentix Corp. | 261.39 Thousand USD | -1121.421% |
| Resverlogix Corp. | 8.11 Million USD | 60.657% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -70.016% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.93% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 93.307% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -399.127% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -13914.74% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 64.324% |
| AVAX Technologies, Inc. | 7.37 Million USD | 56.722% |
| Zenith Capital Corp. | 7410.00 USD | -42986.343% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.906% |
| Ember Therapeutics, Inc. | 184.00 USD | -1735061.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -892.119% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1121.552% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -244.055% |
| Kadimastem Ltd | 2.3 Million USD | -38.567% |
| Helix BioMedix, Inc. | 3.02 Million USD | -5.541% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -5492.003% |
| LadRx Corporation | 2.3 Million USD | -38.339% |
| Cell Source, Inc. | 195.17 Thousand USD | -1535.847% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -802.869% |
| NovAccess Global Inc. | 62.24 Thousand USD | -5028.997% |
| Affymax, Inc. | 7.44 Million USD | 57.105% |
| Itoco Inc. | 1.4 Million USD | -128.038% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3237.652% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -2911.979% |
| Mobile Lads Corp. | 52.00 USD | -6139703.846% |
| CytoDyn Inc. | 11.13 Million USD | 71.33% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2133.093% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -17756.253% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -728.259% |
| SYBLEU INC | 330.46 Thousand USD | -866.114% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -679.806% |
| International Stem Cell Corporation | 5.39 Million USD | 40.766% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2219.634% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 78.718% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 80.743% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -3941.39% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -269.236% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 57.527% |
| Neutra Corp. | 2851.00 USD | -111885.198% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 90.148% |
| PureTech Health plc | 693.97 Million USD | 99.54% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 60.443% |
| IXICO plc | 15.84 Million USD | 79.849% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 61.45% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.91% |
| CSL Limited | 38.02 Billion USD | 99.992% |
| Cellectis S.A. | 333.99 Million USD | 99.044% |